EA201070719A1 - Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты - Google Patents

Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты

Info

Publication number
EA201070719A1
EA201070719A1 EA201070719A EA201070719A EA201070719A1 EA 201070719 A1 EA201070719 A1 EA 201070719A1 EA 201070719 A EA201070719 A EA 201070719A EA 201070719 A EA201070719 A EA 201070719A EA 201070719 A1 EA201070719 A1 EA 201070719A1
Authority
EA
Eurasian Patent Office
Prior art keywords
propanamides
benzylamino
purity
high degree
obtaining
Prior art date
Application number
EA201070719A
Other languages
English (en)
Other versions
EA019898B1 (ru
Inventor
Елена Барбанти
Лаура Фаравелли
Патрисия Сальвати
Ренато Каневотти
Франческо Понзини
Original Assignee
Ньюрон Фармасьютикалс С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньюрон Фармасьютикалс С.П.А. filed Critical Ньюрон Фармасьютикалс С.П.А.
Publication of EA201070719A1 publication Critical patent/EA201070719A1/ru
Publication of EA019898B1 publication Critical patent/EA019898B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification

Abstract

Способ получения терапевтически активных 2-[4-(3- и 2-(фторбензилокси)бензиламино]пропанамидов и их солей с фармацевтически приемлемыми кислотами с высокой степенью чистоты, в частности с содержанием примесей дибензиловых производных менее 0,03, предпочтительно менее 0,01 мас.%. Способ осуществляют, подвергая промежуточные основания Шиффа 2-[4-(3- и 2-фторбензилокси)бензилиденамино]пропанамидов реакции восстановления восстановителем, выбранным из боргидрида натрия и боргидрида калия в соответствующем количестве органического растворителя, выбранного из низших (C-C)-алканолов, обеспечивая образование и присутствие в ходе значительной части реакции восстановления суспензии основания Шиффа в насыщенном растворе основания Шиффа в том же органическом растворителе.
EA201070719A 2007-12-11 2008-12-01 Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты EA019898B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07023937 2007-12-11
PCT/EP2008/066559 WO2009074478A1 (en) 2007-12-11 2008-12-01 Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree

Publications (2)

Publication Number Publication Date
EA201070719A1 true EA201070719A1 (ru) 2010-12-30
EA019898B1 EA019898B1 (ru) 2014-07-30

Family

ID=39301684

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201400105A EA030250B1 (ru) 2007-12-11 2008-12-01 Применение 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты и содержащие их фармацевтические композиции
EA201070719A EA019898B1 (ru) 2007-12-11 2008-12-01 Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201400105A EA030250B1 (ru) 2007-12-11 2008-12-01 Применение 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты и содержащие их фармацевтические композиции

Country Status (27)

Country Link
US (2) US8530701B2 (ru)
EP (2) EP2229351B1 (ru)
JP (2) JP5460613B2 (ru)
KR (2) KR101709498B1 (ru)
CN (2) CN101896456B (ru)
AR (1) AR071267A1 (ru)
AU (1) AU2008334778B2 (ru)
BR (1) BRPI0820657A2 (ru)
CA (2) CA2706789C (ru)
CY (1) CY1119991T1 (ru)
DK (1) DK2229351T3 (ru)
EA (2) EA030250B1 (ru)
ES (2) ES2837000T3 (ru)
HK (2) HK1145673A1 (ru)
HR (1) HRP20180210T1 (ru)
HU (1) HUE036232T2 (ru)
IL (1) IL205872A (ru)
LT (1) LT2229351T (ru)
MX (1) MX2010006278A (ru)
NO (1) NO2229351T3 (ru)
NZ (1) NZ585806A (ru)
PL (1) PL2229351T3 (ru)
PT (1) PT2229351T (ru)
RS (1) RS56803B1 (ru)
SI (1) SI2229351T1 (ru)
TW (1) TWI429425B (ru)
WO (1) WO2009074478A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004266494B2 (en) * 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
AU2007263328C1 (en) * 2006-06-19 2012-09-06 Newron Pharmaceuticals S.P.A. Process for the production of 2- [4 - ( 3- and 2-fluorobenzyloxy) benzylamino] propan amides
EP2229351B1 (en) * 2007-12-11 2017-11-08 Newron Pharmaceuticals S.p.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
EP2314569A1 (en) * 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
HUE030504T2 (en) * 2010-04-27 2017-05-29 Newron Pharm Spa Process for the preparation of ralfinamide methanesulfonate salts or their R-enantiomers
EP2638007A2 (en) 2010-11-11 2013-09-18 Redx Pharma Limited Drug derivatives
CN103044279B (zh) * 2012-12-21 2015-07-08 苏州永健生物医药有限公司 一种n-香豆酰多巴胺的合成方法
WO2015102390A1 (ko) * 2013-12-30 2015-07-09 이화여자대학교 산학협력단 신규한 아미드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 통증의 예방 또는 치료용 약학적 조성물
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
CN105017060B (zh) * 2015-07-03 2017-06-16 南京正大天晴制药有限公司 一种沙芬酰胺新晶型及其制备方法
CN106365966A (zh) * 2015-07-24 2017-02-01 上海医药集团股份有限公司 一种苄基芳基醚的制备方法
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106565442B (zh) * 2016-08-24 2019-07-16 浙江美诺华药物化学有限公司 3-(3-氟苄基)-4-(3-氟苄氧基)苯甲醛的制备方法
CN106349269B (zh) * 2016-08-24 2018-08-31 浙江美诺华药物化学有限公司 2-(3-氟苄氧基)-5-甲酰基苯硼酸及其制备方法
CN106632223B (zh) * 2016-08-24 2019-04-23 浙江美诺华药物化学有限公司 2-(3-溴-4-(3-氟苄氧基)苯基)-1,3-二氧戊环及其制备方法
CN106596828B (zh) * 2016-12-15 2018-09-25 扬子江药业集团有限公司 一种甲磺酸沙芬酰胺有关物质的检测方法
WO2019167085A1 (en) * 2018-03-01 2019-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
WO2020136671A1 (en) * 2018-12-27 2020-07-02 Natco Pharma Limited Improved process for the preparation of lapatinib base and it's anhydrous ditosylate salt
EP3725768A1 (en) * 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
US11111208B2 (en) * 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
US11225457B2 (en) * 2019-08-06 2022-01-18 Medichem, S.A. Process for preparing safinamide
CN113444010B (zh) * 2020-03-28 2023-09-05 南京正大天晴制药有限公司 一种沙芬酰胺有关物质的制备方法
CN112028754A (zh) * 2020-06-17 2020-12-04 浙江美诺华药物化学有限公司 一种甲磺酸沙芬酰胺中间体的制备方法
CN114088830B (zh) * 2021-11-10 2022-09-23 石家庄四药有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
MXPA02009619A (es) * 2000-03-31 2004-07-30 Eruro Celtique S A Aminopiridinas y su uso como anticonvulsivos y bloqueadores del canal de sodio.
ES2253579T3 (es) 2001-09-03 2006-06-01 Newron Pharmaceuticals S.P.A. Composicion farmaceutica que comprende gabapentina o un analogo suyo y una alfa-aminoamida y su uso analgesico.
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
TW200507850A (en) 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
AU2004266494B2 (en) 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
CN101018546B (zh) 2004-09-10 2013-06-12 纽朗制药有限公司 作为钠和/或钙通道选择性调节剂的(卤代苄氧基)苄氨基-丙酰胺类
AU2007263328C1 (en) * 2006-06-19 2012-09-06 Newron Pharmaceuticals S.P.A. Process for the production of 2- [4 - ( 3- and 2-fluorobenzyloxy) benzylamino] propan amides
EP2229351B1 (en) * 2007-12-11 2017-11-08 Newron Pharmaceuticals S.p.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree

Also Published As

Publication number Publication date
CN104523668A (zh) 2015-04-22
IL205872A (en) 2015-06-30
JP6023727B2 (ja) 2016-11-09
EA201400105A1 (ru) 2014-05-30
JP2011506375A (ja) 2011-03-03
KR101593627B1 (ko) 2016-02-11
AU2008334778B2 (en) 2013-05-23
BRPI0820657A2 (pt) 2015-06-16
US20100324141A1 (en) 2010-12-23
EP3257842A1 (en) 2017-12-20
ES2837000T3 (es) 2021-06-29
CN101896456B (zh) 2014-10-22
WO2009074478A1 (en) 2009-06-18
RS56803B1 (sr) 2018-04-30
CA2706789C (en) 2016-09-06
AU2008334778A2 (en) 2010-07-08
EP2229351B1 (en) 2017-11-08
JP2014159407A (ja) 2014-09-04
HRP20180210T1 (hr) 2018-03-09
HK1204960A1 (en) 2015-12-11
TW200932209A (en) 2009-08-01
US8530701B2 (en) 2013-09-10
HK1145673A1 (en) 2011-04-29
EP3257842B1 (en) 2020-11-18
LT2229351T (lt) 2018-01-25
PL2229351T3 (pl) 2018-04-30
KR20100103571A (ko) 2010-09-27
JP5460613B2 (ja) 2014-04-02
CA2936209C (en) 2020-02-11
AU2008334778A1 (en) 2009-06-18
SI2229351T1 (en) 2018-02-28
DK2229351T3 (en) 2018-01-22
IL205872A0 (en) 2010-11-30
NO2229351T3 (ru) 2018-04-07
US8846763B2 (en) 2014-09-30
AR071267A1 (es) 2010-06-09
EA019898B1 (ru) 2014-07-30
EA030250B1 (ru) 2018-07-31
NZ585806A (en) 2011-09-30
US20140051758A1 (en) 2014-02-20
HUE036232T2 (hu) 2018-06-28
TWI429425B (zh) 2014-03-11
CN101896456A (zh) 2010-11-24
ES2655706T3 (es) 2018-02-21
EP2229351A1 (en) 2010-09-22
PT2229351T (pt) 2018-01-19
KR101709498B1 (ko) 2017-02-23
CN104523668B (zh) 2020-06-09
CA2936209A1 (en) 2009-06-18
KR20160017140A (ko) 2016-02-15
CY1119991T1 (el) 2018-12-12
MX2010006278A (es) 2010-08-31
CA2706789A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
EA201070719A1 (ru) Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты
AR074845A1 (es) Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
RS53824B1 (en) PROCESS FOR OBTAINING 2- [4- (3-AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDE
DK2473045T3 (en) Niacin-FATTY ACID CONJUGATES AND THEIR USES
Young et al. Inhibition of inducible nitric oxide synthase by acetamidine derivatives of hetero-substituted lysine and homolysine
NO20070295L (no) Nye CIS-imidazoliner
PE20060662A1 (es) Procedimiento para producir derivados de amina opticamente activos
JP2008255122A5 (ru)
PE20091888A1 (es) Inhibidores de catepsina c
US9732037B2 (en) 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors
TW200718688A (en) Fluorinated ryridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls
AR075978A1 (es) Procedimiento de sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
NO20082005L (no) Syntese av renininhibitorer omfattende en cyklotilfoyelsesreaksjon
AR075977A1 (es) Procedimiento de sintesis de ivabradina y/o su derivado amino hidrogenado y de sus sales de adicion a un acido farmaceuticamente aceptable e intermediarios de sintesis.
CN116496205A (zh) 一种卡瑞斯汀的盐及其用途
AR060622A1 (es) Proceso para la preparcion del ester 2-[ 4-(4- fluoro-2 - metil-1h -indol-5- iloxi)-5-metil pirrolo [2,1-f] [ 1,2,4] triazin -6-iloxi] -1- metiletilico del acido [(1r),2s ] -2- aminopropinoico
EP2751071B1 (en) Fatty acid amides, compositions and methods of use
Curtin et al. Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770
MX2010005039A (es) Derivados de quinolina y su uso como inhibidores de tirosina quinasa.
JP6054875B2 (ja) ジスルフィドの水素化による芳香族チオール誘導体の調製方法
JP2006524208A5 (ru)
ATE509619T1 (de) Herstellungsverfahren für eine feste dispersion mit itraconazol
KR20170010059A (ko) 치료적 화합물로서 신규한 ep4 작용제
WO2008155334A3 (en) Improved process of amide formation
MA35806B1 (fr) Nouveau procede de synthese du 3-(2-bromo-4,5-dimethoxyphenil) propanenitrile, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable